Using Pharmacogenetics in Real Time to Guide Warfarin Initiation A Clinician Update

被引:40
作者
Carlquist, John F.
Anderson, Jeffrey L. [1 ]
机构
[1] Intermt Med Ctr, Cardiovasc Dept, Murray, UT 84107 USA
关键词
GENETIC-POLYMORPHISM; CYP2C9; ANTICOAGULATION; GENOTYPE; P-4502C9; PREDICT; IMPACT; MODEL;
D O I
10.1161/CIRCULATIONAHA.111.019737
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:2554 / 2559
页数:6
相关论文
共 31 条
[1]   Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].
Anderson, Jeffrey L. ;
Horne, Benjamin D. ;
Stevens, Scott M. ;
Grove, Amanda S. ;
Barton, Stephanie ;
Nicholas, Zachery P. ;
Kahn, Samera F. S. ;
May, Heidi T. ;
Samuelson, Kent M. ;
Muhlestein, Joseph B. ;
Carlquist, John F. .
CIRCULATION, 2007, 116 (22) :2563-2570
[2]   CYP4F2 genetic variant alters required warfarin dose [J].
Caldwell, Michael D. ;
Awad, Tarif ;
Johnson, Julie A. ;
Gage, Brian F. ;
Falkowski, Mat ;
Gardina, Paul ;
Hubbard, Jason ;
Turpaz, Yaron ;
Langaee, Taimour Y. ;
Eby, Charles ;
King, Cristi R. ;
Brower, Amy ;
Schmelzer, John R. ;
Glurich, Ingrid ;
Vidaillet, Humberto J. ;
Yale, Steven H. ;
Zhang, Kai Qi ;
Berg, Richard L. ;
Burmester, James K. .
BLOOD, 2008, 111 (08) :4106-4112
[3]   CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study [J].
Caraco, Y. ;
Blotnick, S. ;
Muszkat, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) :460-470
[4]   Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing [J].
Carlquist, John F. ;
McKinney, Jason T. ;
Nicholas, Zachary P. ;
Clark, Jessica L. ;
Kahn, Samera F. ;
Horne, Benjamin D. ;
Muhlestein, Joseph B. ;
May, Heidi T. ;
Anderson, Jeffrey L. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 26 (01) :1-7
[5]   Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose:: a prospective study [J].
Carlquist, John F. ;
Horne, Benjamin D. ;
Muhlestein, Joseph B. ;
Lappe, Donald L. ;
Whiting, Bryant M. ;
Kolek, Matthew J. ;
Clarke, Jessica L. ;
James, Brent C. ;
Anderson, Jeffrey L. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2006, 22 (03) :191-197
[6]   Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design [J].
Do, E. J. ;
Lenzini, P. ;
Eby, C. S. ;
Bass, A. R. ;
McMillin, G. A. ;
Stevens, S. M. ;
Woller, S. C. ;
Pendleton, R. C. ;
Anderson, J. L. ;
Proctor, P. ;
Nunley, R. M. ;
Davila-Roman, V. ;
Gage, B. F. .
PHARMACOGENOMICS JOURNAL, 2012, 12 (05) :417-424
[7]   Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study) [J].
Epstein, Robert S. ;
Moyer, Thomas P. ;
Aubert, Ronald E. ;
O'Kane, Dennis J. ;
Xia, Fang ;
Verbrugge, Robert R. ;
Gage, Brian F. ;
Teagarden, J. Russell .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (25) :2804-2812
[8]   Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy [J].
Ferder, N. S. ;
Eby, C. S. ;
Deych, E. ;
Harris, J. K. ;
Ridker, P. M. ;
Milligan, P. E. ;
Goldhaber, S. Z. ;
King, C. R. ;
Giri, T. ;
McLeod, H. L. ;
Glynn, R. J. ;
Gage, B. F. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) :95-100
[9]   Genetic Warfarin Dosing Tables Versus Algorithms [J].
Finkelman, Brian S. ;
Gage, Brian F. ;
Johnson, Julie A. ;
Brensinger, Colleen M. ;
Kimmel, Stephen E. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (05) :612-618
[10]   Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial [J].
French, Benjamin ;
Joo, Jungnam ;
Geller, Nancy L. ;
Kimmel, Stephen E. ;
Rosenberg, Yves ;
Anderson, Jeffrey L. ;
Gage, Brian F. ;
Johnson, Julie A. ;
Ellenberg, Jonas H. .
TRIALS, 2010, 11